{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T05:34:46Z","timestamp":1795152886683,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity\/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed\/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005\u20132020 with novel agent-based triplet\/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091333) and three validation cohorts (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection\/death were identified: low platelet count (&lt;150\/nL), ISS III, higher WHO performance status (&gt;1), and age (&gt;60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; \u22652 points) risk. The risk for severe infection\/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection\/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65\/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02\/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-02105-6","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T06:04:35Z","timestamp":1701929075000},"page":"640-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-0814","authenticated-orcid":false,"given":"Hans J.","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pantani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-0129","authenticated-orcid":false,"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor W.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-2671","authenticated-orcid":false,"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"von Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-7710","authenticated-orcid":false,"given":"Ullrich","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-5209","authenticated-orcid":false,"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-3227","authenticated-orcid":false,"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"2105_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138.","journal-title":"Leukemia"},{"key":"2105_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"I Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101:237\u201344.","journal-title":"Eur J Haematol"},{"key":"2105_CR3","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219\u201326.","journal-title":"J Clin Oncol"},{"key":"2105_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica"},{"key":"2105_CR5","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","volume":"32","author":"P Moreau","year":"2014","unstructured":"Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of International Scoring System 3, high lactate dehydrogenase, and t(4;14) and\/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression\u2013related death. J Clin Oncol. 2014;32:2173\u201380.","journal-title":"J Clin Oncol"},{"key":"2105_CR6","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","volume":"32","author":"C Dumontet","year":"2018","unstructured":"Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, et al. A predictive model for risk of early grade\u22653 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018;32:1404\u201313.","journal-title":"Leukemia"},{"key":"2105_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.07.003","volume":"130","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. Crit Rev Oncol Hematol. 2018;130:27\u201335.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2105_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","volume":"67","author":"BW Teh","year":"2016","unstructured":"Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. Eur J Cancer. 2016;67:21\u201337.","journal-title":"Eur J Cancer"},{"key":"2105_CR9","doi-asserted-by":"publisher","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget. 2017;8:46593\u2013600.","journal-title":"Oncotarget"},{"key":"2105_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211\u201325.","journal-title":"Clin Infect Dis"},{"key":"2105_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2019","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2019;34:224\u201333.","journal-title":"Leukemia"},{"key":"2105_CR12","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068\u201374.","journal-title":"Blood"},{"key":"2105_CR13","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IGH, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946\u201355.","journal-title":"J Clin Oncol"},{"key":"2105_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia. 2018;32:383\u201390.","journal-title":"Leukemia"},{"key":"2105_CR15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, D\u00fcrig J, Kunz C, Haenel M, Blau IW, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29:1721\u20139.","journal-title":"Leukemia"},{"key":"2105_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","volume":"34","author":"H Goldschmidt","year":"2020","unstructured":"Goldschmidt H, Mai EK, D\u00fcrig J, Scheid C, Weisel KC, Kunz C, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34:1853\u201365.","journal-title":"Leukemia"},{"key":"2105_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2021-147323","volume":"138","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Besemer B, Haenel M, Miah K, et al. Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: Results from the randomized Phase III GMMG-HD6 trial. Blood. 2021;138:486.","journal-title":"Blood"},{"key":"2105_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5600-x","volume":"19","author":"H Salwender","year":"2019","unstructured":"Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, et al. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction\/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer. 2019;19:504.","journal-title":"BMC Cancer"},{"key":"2105_CR19","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u201368.","journal-title":"Lancet Haematol"},{"key":"2105_CR20","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet. Haematol. 2022;9:e810\u201321.","journal-title":"Lancet. Haematol."},{"key":"2105_CR21","doi-asserted-by":"publisher","first-page":"v45\/i01","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"Svan Buuren","year":"2011","unstructured":"Buuren Svan, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45:v45\/i01. http:\/\/www.jstatsoft.org\/v45\/i03.","journal-title":"J Stat Softw"},{"key":"2105_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"2105_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00652-2","volume":"12","author":"C Encinas","year":"2022","unstructured":"Encinas C, Hernandez-Rivas J-\u00c1, Oriol A, Rosi\u00f1ol L, Blanchard MJ, Bell\u00f3n JM, et al. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:68.","journal-title":"Blood Cancer J"},{"key":"2105_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.24796","volume":"92","author":"H Terebelo","year":"2017","unstructured":"Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, et al. Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol. 2017;92:915\u201323.","journal-title":"Am J Hematol"},{"key":"2105_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20:1760\u201372.","journal-title":"Lancet Oncol"},{"key":"2105_CR26","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u2013e161.","journal-title":"Lancet Haematol"},{"key":"2105_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29\u201337.","journal-title":"Lancet Oncol"},{"key":"2105_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41375-018-0195-9","volume":"33","author":"EK Mai","year":"2019","unstructured":"Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, et al. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia. 2019;33:258\u201361.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02105-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02105-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02105-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T09:05:05Z","timestamp":1709543105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02105-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02105-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following potential conflicts of interest: EKM: consulting or advisory role, honoraria, research funding, and travel accommodations\/expenses from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda. TH and UB: no competing interests. HJS: advisory role or honoraria from AbbVie, Amgen, Bristol Myers Squibb\/Celgene, Chugai, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Roche, Sanofi, Sebia, TAD, and Takeda; travel accommodation\/expenses from Amgen, Bristol Myers Squibb\/ Celgene, GlaxoSmithKline, Janssen-Cilag, and Sanofi. SZ: consulting or advisory role for Janssen-Cilag, Bristol Myers Squibb, Sanofi, Oncopeptides, and Takeda (all payments to the institution); research funding from Janssen-Cilag and Takeda. MSR: consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Novartis, Roche, and Sanofi; honoraria from AbbVie and GlaxoSmithKline; research funding from Novartis and Sanofi. MM: consulting or advisory role for AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Takeda; honoraria from Amgen, Bristol Myers Squibb, Janssen, and Takeda; research funding from Incyte; travel accommodation\/expenses from Amgen. LP honoraria from Sanofi, GlaxoSmithKline, and Pfizer. KM: honoraria from Amgen, Bristol-MyersSquibb\/Celgene, Janssen, Takeda, Sanofi, GlaxoSmithKline, and Pfizer. PB: no competing interests. MB: consulting or advisory role for Janssen, Celgene\/Bristol Myers Squibb, Amgen, Sanofi, Takeda, and Menarini; speaker\u2019s bureau for Amgen, Takeda, Sanofi, and Celgene\/Bristol Myers Squibb. IWB: no competing interests. JD: consulting or advisory role for Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda, Celgene, and Roche; travel accommodation\/expenses from Roche, Celgene, and Bristol Myers Squibb. BB: honoraria from Janssen, GlaxoSmithKline, Amgen, and Sanofi. RF: honoraria from Bristol Myers Squibb\/Celgene, Janssen, Sanofi, and GlaxoSmithKline; consulting or advisory role for Bristol Myers Squibb\/Celgene, Janssen, and GlaxoSmithKline; travel accommodations\/expenses from Bristol Myers Squibb\/Celgene, Janssen, and GlaxoSmithKline. PR and BvdH: no competing interests. MH: consulting or advisory role for Amgen, Bayer Vital, Bristol Myers Squibb\/Celgene, Gilead, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, Roche, and Takeda; invitation as speaker for Novartis. IvM: consulting or advisory role for Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; honoraria from Sanofi; travel accommodations\/expenses from Takeda. UG: stock and other ownership interests for Biontech; honoraria from Boehringer Ingelheim, Amgen, Astra Zeneca, Bristol Myers Squibb\/Celgene, MSD Oncology, Sanofi Aventis, Fujifilm, Novartis, and Celltrion; consulting or advisory role for Amgen, MSD oncology; research funding from Ipsen (to the institution), Macrogenics (to the institution); travel accommodations\/expenses from Boehringer Ingelheim and GlaxoSmithKline. CM-T: <b>r<\/b>esearch funding from Pfizer and BioliveRx. MB: honoraria from AbbVie, Amgen, Bristol-Myers Squibb\/Celgene, Janssen, Novartis, and Sanofi. CS: honoraria from AbbVie, Amgen, Bristol Myers Squibb, Glaxo Smith Kline, Janssen, Pfizer, Oncopeptides, Sanofi, and Takeda; travel accommodation\/expenses from Bristol Myers Squibb, Janssen, Novartis, and Takeda; research funding from Janssen, Novartis, and Takeda. MAD: honoraria from Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, BeiGene, and Sanofi; consulting or advisory role for Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, BeiGene, and Sanofi. JH: consulting or advisory role for Adaptive, Amgen, Axxes Network, Bristol Myers Squibb\/Celgene, Glaxo Smith Kline, Janssen, Oncopeptides, Oncotracker, Sanofi, and Skyline; invited talks for Amgen, Beigene, Beijing Medical Award Foundation, Curio Science, and Janssen. KCW: honoraria from Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Bristol Myers Squibb\/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda; consulting or advisory role for Abbvie, Amgen, Adaptive Biotech, Bristol Myers Squibb\/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda; research funding from Amgen (to the institution), Bristol Myers Squibb\/Celgene (to the institution), Janssen (to the institution), and Sanofi (to the institution). MC: consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb, GSK, Janssen, Pfizer, and Sanofi; speaker\u2019s bureau for Bristol Myers Squibb and Janssen. PS: consulting or advisory role for Celgene\/Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi; research funding from Celgene\/Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi. HG: consulting for Adaptive Biotechnology, Amgen, Bristol Myers Squibb, and Janssen; honoraria from Amgen, Bristol Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, and Novartis; research funding from Amgen, Bristol Myers Squibb, Celgene, Chugai, Incyte, Janssen, Molecular Partner, MSD, Mundipharma, and Novartis; grants from Amgen, Celgene, Chugai, Janssen, and Johns Hopkins University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}